Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning

<p class="MsoNormal">Featuring an interview with Dr Matthew Lunning, including the following topics:</p> <ul> <li>Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00)</li> <li>Overview of the CAR T-cell therapy administration process (4:40)</li> <li>Opportunities for referral for CAR T-cell therapy (10:05)</li> <li>Selection of a CAR T-cell therapy based on patient characteristics (16:09)</li> <li>Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23)</li> <li>Safety regulations and mitigation strategies for adverse events (30:36)</li> <li>Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16)</li> <li>Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09)</li> <li>Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09)</li> </ul> <p class="MsoNormal"><a href= "http...